BioNTech’s Transformation Underway: €500M in Savings, New Board, and Pumitamig’s ASCO Moment

BioNTech reports €531.9M net loss in Q1 2026 with €557M R&D spend, launches restructuring to save €500M annually by 2029, and awaits pivotal Pumitamig data at ASCO.

The transition from pandemic-era powerhouse to oncology contender is proving costly for BioNTech. In the first quarter of 2026, the company reported a net loss of €531.9 million, with research spending alone hitting €557 million. Yet the balance sheet remains formidable: €16.8 billion in cash and securities provides ample runway. The trick will be spending wisely — and a recently authorized $1 billion share buyback program signals management’s confidence in its own stock as well as its pipeline.

To bridge the gap to profitability, BioNTech is embarking on a sweeping restructuring. Manufacturing capacity will be consolidated, with the goal of achieving roughly €500 million in annual cost savings by 2029. The savings target reflects the reality that COVID-19 vaccine revenue is fading; the company’s full-year 2026 guidance of €2.0 billion to €2.3 billion in revenue factors in both waning demand and the expiry of pandemic-era multi-year contracts in Europe.

On the governance front, the annual general meeting — representing 92% of share capital — approved enlarging the supervisory board from six to eight members. Two new faces join the roster: Prof. Iris Löw-Friedrich, who brings clinical development expertise, and Dr. Susanne Schaffert, a veteran of international oncology marketing. Helmut Jeggle retains the chairmanship. Analysts see the expansion as a preparatory move for forthcoming regulatory submissions from BioNTech’s late-stage pipeline, requiring stronger oversight structures.

The immediate spotlight, however, falls on a single drug candidate: Pumitamig. With the ASCO conference’s embargo lifting late Thursday afternoon, the market will finally see data from the Phase?2 ROSETTA Lung-02 study. Pumitamig is being tested in combination with chemotherapy as a first-line treatment for non-small-cell lung cancer, going head-to-head against the established standard-of-care, Merck’s Keytruda (pembrolizumab). The stakes are enormous. BioNTech has already expanded Pumitamig’s clinical program with two new studies, including one targeting Stage?III lung cancer, and this year launched five registration-directed trials in collaboration with Bristol?Myers?Squibb. The BMS partnership alone carries potential milestone payments of up to $7.6 billion.

Adding to the sense of a changing of the guard, CEO Ugur Sahin indicated at the AGM that he may have just delivered his final address as chairman. The leadership transition will be accompanied by an operational handoff: from the end of 2026, partner Pfizer will assume full commercial production of the COVID-19 vaccines, freeing BioNTech to channel all resources into oncology.

Beyond Pumitamig, other pipeline catalysts are on the horizon. Later this year, the company expects interim results from a Phase?3 study of the antibody gotistobart, with primary data collection for that trial concluding as soon as June. The clinical calendar is dense, and regulatory submissions in the second half of 2026 could provide the next major inflection point.

Investors have not been patient. The stock closed at €77.65, roughly 24% below its year-to-date high and about 17% lower than 30 days ago. The shares now trade about 10% beneath their 200-day moving average. For a company sitting on nearly €17 billion in cash and a pipeline that could reshape its identity, the next few months will determine whether the sell-off was a buying opportunity or a precursor to more disappointment.